Main Article Content


Over the last few years, there is tremendous growth of melanoma skin cancer in all around the world. Paclitaxel is an antineoplastic drug which is widely used for breast cancer, lung cancer, and Kaposi sarcoma. It is available only in the form of intravenous (IV), which produces tissue damage and hypersensitivity in some patients if the dose is over. In the present article, the new initiative formulation is done for melanoma skin cancer with transfersomes drug delivery systems. A different formulation of transfersomes is prepared using Span. The various characterization is done for the transfersomes like morphology, entrapment efficacy, in vitro drug release dialysis bag method. By using the Carbopol 940, the transfersomes gel was prepared. Paclitaxel-loaded transfersomes (FS-2) shows the positive entrapment efficacy 68.2% and the vesicle size 200 nm. From the in vitro dialysis bag method, FS-2 showed the high rate of drug release by nearly 72% in 12 hrs. we conclude that this will be the initial step for the further studies of melanoma skin cancer and provide the better treatment for skin cancer.


Transfersomes Melanoma skin cancer Edge activator Transdermal delivery system

Article Details

How to Cite
Sivarajakumar Raahulan, Bharat Kumar Reddy Sanapalli, & Veera Venkata Satyanarayana Reddy Karri. (2019). Paclitaxel loaded transfersomal vesicular drug delivery for the treatment of melanoma skin cancers. International Journal of Research in Pharmaceutical Sciences, 10(4), 2891-2897.